Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Entrectinib in NTRK-fusion positive gastrointestinal cancers

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.07.19
Views: 264

Prof Salvatore Siena - Università degli Studi di Milano Statale, Milan, Italy

Prof Salvatore Siena speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about the use of entrectinib in NTRK-fusion positive gastrointestinal cancers.

The results were taken from an integrated analysis based on patients in three trials - STARTRK-2, STARTRK-1 and ALKA-372-001.

Prof Siena reports that entrectinib was very well tolerated and induced clinically meaningful, durable responses in select patients.

 

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation